Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weekly shot shows promise for obesity – but It's early days

NCT ID NCT06857617

Disease control Sponsor: Metsera, a wholly owned subsidiary of Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called MET097, given as a weekly injection, to see if it is safe and helps with weight loss in adults who are overweight or obese but otherwise healthy. About 120 participants will receive either MET097 or a placebo for up to 12 weeks, with some exploring a once-monthly dose. The goal is to measure weight change and how the drug behaves in the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MET097 (a biologic injection)
What this could lead to
If successful, this could lead to a new once-weekly or even once-monthly injection to help people with obesity lose weight.
What could go wrong
This is an early Phase 1/2 trial with only 120 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

120 people

The number who actually took part.

Started

Apr 2024

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Overweight/Obese but otherwise healthy adult male or female with a BMI within 27.0 kg/m2 to 38.0 kg/m2, inclusively * At least 18 years of age but not older than 70 years of age * Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on the physical examination (including vital signs) and/or ECG, as determined by an Investigator * Estimated glomerular filtration rate (eGFR) ≥90 mL/min at the Screening visit Exclusion Criteria: * Female who is lactating or who is pregnant according to the pregnancy test at the Screening visit or prior to the first study drug administration * Seated blood pressure higher than 160/95 mmHg at the Screening visit * Elevated resting pulse greater than 100 beats per minute at Screening visit * Presence of clinically significant ECG abnormalities * Diagnosis of diabetes (type 1 or type 2) * Participation in a weight loss program with or without pharmacotherapy during the 3 months prior to study administration * Obesity induced by endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., Melanocortin 4 Receptor deficiency or Prader-Willi Syndrome). * Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity and overweight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity and overweight

Contacts and locations

Locations

  • Research Site MET097 23-101-001

    Overland Park, Kansas, 66212, United States

  • Research Site MET097 23-101-002

    Anaheim, California, 92801, United States

  • Research Site MET097 23-101-003

    Cypress, California, 90630, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.